Biovica International
19.11.2021 16:17:02 CET | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / November 19, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II)
Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.
Biovica and Carrick Therapeutics have collaborated on generating TK activity (TKa) data in the phase 1/2A study of samuraciclib (NCT033638939), a first-in-class, oral, selective inhibitor of CDK7 that recently received fast track designation from the US Food and Drug Administration (FDA). The study demonstrates the potential association of TKa levels with treatment effect for this next generation CDK inhibitor.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
DiviTum®TKa results from the clinical study PROMISE (NCT03281902) conducted at the Mayo Clinic show the association of TKa with progression free survival. The study results are a continuation of the results presented on SABCS 2020. Since then, the study has continued and samples from almost twice as many patients have been tested for TKa, with the new results confirming the initial analysis and earlier DiviTum®TKa results - i.e., the usage of DiviTum®TKa as a valuable tool in the evaluation of treatment effect in metastatic breast cancer.
P5-13-22 Serum thymidine kinase 1 activity (TKa) levels and progression-free survival (PFS) in patients (pts) with hormone receptor positive (HR+) HER2-negative metastatic breast cancer (MBC) on palbociclib (Pb) and endocrine therapy (ET)
Additional results of the healthcare DiviTum®TKa Budget Impact Model show the potential for DiviTum®TKa to substantially reduce the number of CT scans and bone scans used in monitoring women with metastatic breast cancer. As these scans are both costly and a burden on patients, this reinforces the potential benefit of DiviTum®TKa to healthcare systems and to patients. Additionally, the test may enable early identification when a treatment is not effective and therefore enable overall savings of three times the added spend on the DiviTum®TKa test.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
"The data on DiviTum®TKa being presented at SABCS strengthens the scientific and economic foundation for the role of the test in the care of breast cancer patients. We are very pleased with these results," said Anders Rylander, CEO of Biovica.
The San Antonio Breast Cancer Symposium, SABCS, runs December 7-10, 2021.
Contact:
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.
Attachments
Biovica's DiviTum®TKa in three studies at SABCS 2021
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/673809/Biovicas-DiviTumRTKa-in-Three-Studies-at-SABCS-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution17.3.2026 15:05:00 CET | Press release
Redshift for Vectorworks now available, Autodesk Revit® beta open for sign-ups, and Graphisoft Archicad releasing later in 2026. Maxon unveils a deeper look at its end-to-end 3D workflow for architects and designers in 2026 and beyond. BAD HOMBURG, DE / ACCESS Newswire / March 17, 2026 / Maxon, maker of powerful, approachable software solutions for creators working in 2D and 3D design, motion graphics, visual effects, gaming, and more, today announced the commercial availability of Redshift for Vectorworks. Additionally, the company announced the beta launch of Redshift for Autodesk Revit®. This marks the next major milestone in Maxon's expansion into the Architecture, Engineering & Construction (AEC) market, with additional integrations planned. Engineered for architects and interior designers, Maxon's AEC solution brings the company's industry-proven cinematic rendering technology, Redshift, and the creative depth of Cinema 4D directly into professional archviz workflows. Designed as
Sauce Labs CEO, Prince Kohli, Says $1 Trillion Software Quality Industry Has Been "Building Wrong" for 20 Years17.3.2026 15:00:00 CET | Press release
The new Sauce AI for Test Authoring launch targets the most labor-intensive slice of the 22% of IT budgets spent on quality assurance, by shifting engineering teams from writing test cases to specifying business intent that the platform autonomously turns into self-improving test suites. SAN FRANCISCO, CA / ACCESS Newswire / March 17, 2026 / Sauce Labs Inc., the world's largest full-lifecycle, test automation platform, today announced the general availability of Sauce AI for Test Authoring, an AI Agent that translates business intent into framework-agnostic executable test suites that can be run instantly on Sauce Labs' virtual and real-device clouds. This launch introduces a new paradigm for DevOps: Intent-Driven Testing, designed to bridge the "Velocity and Quality Gap", the widening distance between how fast AI generates code and how slowly teams can validate it for enterprise-grade quality. High-quality test creation is one of software development's most persistent bottlenecks. Dev
Datavault AI Schedules Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 202617.3.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / March 17, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today announced that it will report financial results for its fourth quarter and full year 2025 prior to market open on Thursday, March 19, 2026. Following the release, Datavault AI will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Thursday, March 19, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-405-1216 Participant Dial-in (International): 1-201-689-8336 Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here. About Datavault AI Inc. Datavault AI TM (NASDAQ:DVLT) is leading the
Ondas Completes Acquisition of Rotron Aerospace Ltd., Expanding Long-Range Propulsion Technologies for Advanced Unmanned Systems for Defense16.3.2026 13:30:00 CET | Press release
UK-Based Rotron Aerospace Strengthens Ondas' Systems of Systems Architecture with Unmanned Aircraft Platforms, Aero-Engine Technologies, and Long-Endurance Autonomous Mission Capabilities Expands Ondas' Strategic Footprint Within the UK and NATO Ecosystems, Providing Fast-Track Access to Major Programs Through Deep-Rooted Relationships with the UK Ministry of Defence Establishes a UK Industrial Base for Advanced Unmanned Systems Supporting NATO Programs and Allied Defense Localization Initiatives WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / March 16, 2026 / Ondas Inc. (Nasdaq:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous aerial and ground robot intelligence through its Ondas Autonomous Systems (OAS) business unit and private wireless solutions through Ondas Networks, today announced the completion of its acquisition of Rotron Aerospace Ltd. (Rotron), a UK-based developer of advanced unmanned aerial systems and long-range autonomous platforms designed for
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners12.3.2026 11:00:00 CET | Press release
AI technology meets on-the-ground expertise from leading organizations across five continents, accessible to billions of consumers in 50+ languages covering 97% of global internet users. AMSTERDAM, NL / ACCESS Newswire / March 12, 2026 / The Global Anti-Scam Alliance (GASA) launched today Scam.org, an AI-powered platform that provides scam education, prevention, detection, reporting, and victim support in over 50 languages, making it a new global hub, accessible to 97% of the world's internet users. Scam.org is powered by partnerships with OpenAI and leading cybersecurity organizations, AnyTech365, CUBE AI,Falkin, Malwarebytes, Netcraft, ReasonLabs, ScamAdviser, Scamnetic, Seraph Secure and Spamhaus. For personal victim support, Scam.org collaborates with other victim support organizations such as AARPin the USA and ANVINT in Brazil. The platform expects more organizations to join, with plans to build an even stronger and broader coalition, creating a world where people are safer from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom